Login to Your Account



Celgene dangles Crohn's data but stops short of meaningful details

By Marie Powers
News Editor

Monday, September 12, 2016

Celgene Corp. offered tantalizing morsels from its phase Ib study of oral GED-0301  in patients with active Crohn's disease, but the tidbits only prompted speculation about the bigger picture behind the curtain of silence.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription